Stroke, IschemicNCT05092139
Endovascular treatmenT for Acute Ischemic Stroke in China (DETECT2-China)
An observational study of Stroke, Ischemic, run by General Hospital of Shenyang Military Region at 1 site in China.
Trial summary
This is a prospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke, Ischemic
- What is being tested?
- endovascular treatment
- Type of treatment
- Medical device
- How many people
- 3,000 participants
- Where
- 1 siteChina
- Study dates
- 21 Jan 2022to 10 Jan 2025
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: acute ischemic stroke with large vessel oclussion
Who may be able to join
- Age: ≥ 18;
- Ischemic stroke confirmed by head CT or MRI;
- Patients receiving endovascular treatment;
- First ever stroke or pre-stroke mRS≤2;
- signed informed consent.
Who cannot join
- Prestroke mRS≥3;
- Other serious illness that would confound the clinical outcome at 90 days;
- Unavailable neuroimaging data;
- Other unsuitable conditions judged by the investigator
Trial locations and contacts
1 site in 1 country.
About this study
Official title: enDovascular trEatmenT for acutE isChemic sTroke in China (DETECT2-China): a Prospective, National, Multi-center, Registry Study
This is a prospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.
- Conditions
- Stroke, Ischemic
- Being tested
- endovascular treatment
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endovascular treatmentDevice
all enrolled patients must receive endovascular treatment
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with modified Rankin Score 0 to 2
the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
Measured: Day 90
Secondary outcomes (5)
Proportion of patients with modified Rankin Score 0 to 1
the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
Measured: Day 90
Distribution of modified Rankin Score
the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
Measured: Day 90
Changes in National Institute of Health stroke scale (NIHSS)
the minimum and maximum values of NIHSS are 0 and 24, respectively; higher NIHSS mean a worse outcome
Measured: 24 hours, 48 hours, and 2 weeks
Proportion of symptomatic intracranial hemorrhage (sICH)
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
Measured: 48 hours
Proportion of death
death due to any cause
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Oct 2021
- Study start21 Jan 2022
- Primary completion10 Jan 2025
- Study completion10 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Stroke, IschemicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (actual)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- General Hospital of Shenyang Military Region
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hui-Sheng Chen, General Hospital of Shenyang Military Region
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05092139
- Sponsor's protocol ID
- y (2021) 077
- Status last verified
- Mar 2025
- First submitted
- 13 Oct 2021
- Last updated
- 18 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Cui C, Liu L, Chen HS. Association of the neutrophil percentage-to-albumin ratio after endovascular treatment and 3-month clinical outcomes. Front Neurol. 2026 Feb 12;17:1768949. doi: 10.3389/fneur.2026.1768949. eCollection 2026.
PubMed 41766997Liu L, Nguyen TN, Chen HS. Endovascular Treatment for Acute Ischemic Stroke in China: a study protocol for a prospective, national, multi-center, registry study. Front Neurol. 2023 Aug 10;14:1171718. doi: 10.3389/fneur.2023.1171718. eCollection 2023.
PubMed 37638196
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- enDovascular trEatmenT for acutE isChemic sTroke in China (DETECT2-China): a Prospective, National, Multi-center, Registry Study
- ClinicalTrials.gov ID
- NCT05092139
- Acronym / sponsor ID
- y (2021) 077
- Conditions
- Stroke, Ischemic
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,000 participants (actual)
- Lead sponsor
- General Hospital of Shenyang Military RegionUniversity, hospital or other
- Study start
- 21 Jan 2022 (actual)
- Primary completion
- 10 Jan 2025 (actual)
- Study completion
- 10 Jan 2025 (actual)
- First posted
- 25 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- acute ischemic stroke with large vessel oclussion
Key inclusion criteria (5 listed)
- Age: ≥ 18;
- Ischemic stroke confirmed by head CT or MRI;
- Patients receiving endovascular treatment;
- First ever stroke or pre-stroke mRS≤2;
- signed informed consent.
Key exclusion criteria (4 listed)
- Prestroke mRS≥3;
- Other serious illness that would confound the clinical outcome at 90 days;
- Unavailable neuroimaging data;
- Other unsuitable conditions judged by the investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endovascular treatmentall enrolled patients must receive endovascular treatment | Device | – |
Primary outcome
Proportion of patients with modified Rankin Score 0 to 2
Time frame: Day 90
the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
5 secondary outcomes
Proportion of patients with modified Rankin Score 0 to 1
Time frame: Day 90
Distribution of modified Rankin Score
Time frame: Day 90
Changes in National Institute of Health stroke scale (NIHSS)
Time frame: 24 hours, 48 hours, and 2 weeks
Proportion of symptomatic intracranial hemorrhage (sICH)
Time frame: 48 hours
Proportion of death
Time frame: 7 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2025.
- Derived from this study: PubMed 41766997Cui C, Liu L, Chen HS. Association of the neutrophil percentage-to-albumin ratio after endovascular treatment and 3-month clinical outcomes. Front Neurol. 2026 Feb 12;17:1768949. doi: 10.3389/fneur.2026.1768949. eCollection 2026.
- Derived from this study: PubMed 37638196Liu L, Nguyen TN, Chen HS. Endovascular Treatment for Acute Ischemic Stroke in China: a study protocol for a prospective, national, multi-center, registry study. Front Neurol. 2023 Aug 10;14:1171718. doi: 10.3389/fneur.2023.1171718. eCollection 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Stroke, Ischemic
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke, Ischemic, run by General Hospital of Shenyang Military Region at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with modified Rankin Score 0 to 2 (time frame: Day 90). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05092139, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2025.